Absorption Systems, a Pharmaron company, is a full-service nonclinical CRO developing innovative services and solutions for the pharmaceutical, biotech, medical device and regenerative medicine industry. Our services include research and testing for small molecules, large molecules, biologics, medical device and cell and gene therapy products. The company's mission is to continually develop innovative research tools that can be used to accurately predict human outcomes or to explain unanticipated outcomes when they occur. The company's facilities are strategically located in Philadelphia, San Diego, and Boston, servicing hundreds of customers throughout the world. Our focus is to maintain accuracy, timelines, and reliability at every stage of development. For more information on the company's comprehensive contract services and applied research programs, please visit absorption.com.
Kemwell is a contract biologics development and CMO company providing services to global biopharmaceutical organizations. Kemwell facilities, located in Bangalore, India, are designed and developed with technological support from a leading German pharma company. Kemwell provides customers with cost-effective access to state-of-the-art technology for all mammalian cell culture based products’ development and manufacturing.
15,000 sq. m. Kemwell facility consists of a cGMP drug substance manufacturing area with over 4500L bioreactor capacity, sterile fill and finish areas for cGMP drug product manufacturing and process development laboratories to support production of protein therapeutics from mammalian-cell culture – monoclonal antibodies, bi-specific antibodies, fusion proteins, etc. Kemwell is capable of supporting novel, bio-better and biosimilar programs’ preclinical development, clinical development, cGMP clinical manufacturing and cGMP commercial manufacturing.
Kemwell, having established in 1980, had long term associations with pharma majors such as Bayer, GlaxoSmithKline, Merck KGaA, Novartis, Pfizer and others for small molecule contract mfg. and R&D. In 2016, Kemwell divested its small-molecule division to focus on biologics, leveraging its vast and rich experience. Kemwell is now a 100% biologics CDMO.
MicroConstants is a GLP-compliant Contract Research Organization focused on performing regulated bioanalysis, drug metabolism, and pharmacokinetic analysis to support discovery, preclinical, and clinical drug development studies. We specialize in method development, validation, and sample analysis of small molecules, macromolecules, biomarkers, and metabolites using LC/MS/MS, HPLC/UV, immunoassay, multiplex, and qPCR techniques.
Since 1998, we have been advancing the drug discovery and development programs of pharmaceutical and biotech companies worldwide. To learn more, please visit http://www.microconstants.com.
PPC Group, a North Asia based full-service CRO founded in 1997, offering a broad range of clinical research services, laboratory and site management services. PPC group has over 23 years’experience in Asia pacific, with headquarters in Shanghai, PPC Group is a subsidiary of Novotech Health Holdings which has over 1550 employees, operating 21 offices across 12 geographies and manage PhaseⅠClinical Pharmacology Units, 4 Bioanalytical Labs (Small Molecule and Large Molecule laboratories) and a Central Laboratory.
Novotech Health Holdings has supported more than 800 customers, performing over 3700 phaseⅠ-Ⅳ clinical trials conducted in over 24 therapeutic areas. PPC Group is the first CRO in Asia who has undergone inspections from all major international regulatory agencies (NMPA, US FDA, EMA, MFDS and PMDA), all resulting in the successful registration of the client’s products. We pride ourselves on understanding the unique set of challenges faced by emerging biopharma companies and are devoted to over-come their challenges and help them maximize their asset value at every stage.
Sai Life Sciences is built on the bedrock of partnership. We work with innovator pharma and biotech companies to accelerate the discovery, development and manufacture of complex small molecules for a healthier tomorrow. Our Vision is to support our global innovator partners bring 25 new medicines to life by 2025. And we are well on that journey.